Evaluation of the Fibroblast Growth Factor 21 as a potential marker on neurogenic hypertension

• Grant number: 23/11230-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2023
• End date: October 31, 2024
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Principal Investigator: Vagner Roberto Antunes
• Grantee: Pedro Sousa Soares
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Cardiovascular diseases (CVDs) represent one of the main causes of premature death worldwide. In Brazil, CVDs, including acute myocardial infarction (AMI) and stroke are responsible for a significant portion of deaths. Systemic arterial hypertension (SAH) is an important risk factor in the development of these conditions and is often responsible for deaths. The cause of essential SAH is multifactorial and polygenic, and there is strong evidence that confirms the involvement of the autonomic nervous system (ANS) in the genesis of SAH and emphasizes the involvement of the sympathetic system in established hypertensive state, a phase in which the sympathetic hypertonia plays a significant role in maintaining high blood pressure levels. There are several studies suggesting that several genetic polymorphisms can influence the genesis and maintenance of SAH, as well as provide greater susceptibility to complications arising from this disease. Fibroblastic Growth Factor 21 (FGF21) is a hormone whose dysfunction has been associated with metabolic disorders, disorders that can lead to the development of SAH. Clinical studies and in experimental animal models of hypertension and metabolic syndrome demonstrate an increase in serum levels of this hormone, of a compensatory nature, suggesting a protective effect against damage to target organs. Thus, this project aims to evaluate the relationship of FGF-21 in the genesis and maintenance of hypertension, as a potential biomarker of this pathology. For this, serum and tissue levels of the hormone and mRNA levels of its main receptor (FGFR1) and coreceptor (beta-klotho - KLB). In addition, we will evaluate the expression of FGF-21 mRNA and its receptors in target organs, such as the brain, heart and kidneys, using the technique of reverse transcription by polymerase chain reaction and its correlations with the development of hypertension.